Categories Earnings, Technology
As Facebook (FB) prepares for Q1 2019 earnings, here’s what to expect
Facebook Inc. (NYSE: FB) is scheduled to report first quarter 2019 earnings results on Wednesday, April 24, after the market closes. Analysts expect the company to report earnings of $1.63 per share on revenue of $14.97 billion.
Facebook is recovering from a tough year of security breaches and management issues but it still faces a few hurdles. The company is seeing slow revenue growth and pressure on profits from higher spending needed to implement security measures on its platform. Facebook is estimated to spend close to $4 billion this year to boost safety on its website.
The social media giant has its share of litigation issues and might face fines that could run into billions of dollars, even as Facebook’s CEO Mark Zuckerberg appears to favor federal regulation that several parties have been advocating in recent times.
Despite its troubles, Facebook has reasons to be optimistic. The company’s advertising revenue is expected to stay strong even as it faces competition from Google and Twitter (TWTR) in the digital ads space, with momentum in mobile advertising.
In spite of the data privacy scandals, Facebook is likely to see a growth in user count, especially from the Asia-Pacific region. The popularity of its existing features like video, coupled with the addition of new features like music, are likely to help improve user engagement.
Last quarter, Facebook topped earnings and revenue estimates, giving the stock a lift of 7% at the time. Earnings grew 65% year-over-year to $2.38 per share, despite the increase in expenses. Revenues grew 30% to $16.9 billion.
Facebook’s shares have gained 35% thus far this year but are still down about 17% from their 52-week high. The stock was up 1.17% in mid-day trade on Monday.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on